Additional Study Information: To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas (including breast cancer, esophageal cancer, lung cancer, sarcomas - bone and soft tissue), thyroid cancer, cervical cancer, ovarian cancer, Hodgkin's disease, non-Hodgkin's lymphoma, pancreatic cancer, colon and rectal cancer, head and neck cancers, skin cancers, melanoma, prostate cancer, and testicular cancer).